{"nctId":"NCT02963766","briefTitle":"A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes","startDateStruct":{"date":"2016-12-29","type":"ACTUAL"},"conditions":["Type 2 Diabetes"],"count":154,"armGroups":[{"label":"Placebo/0.75 milligram (mg) Dulaglutide","type":"EXPERIMENTAL","interventionNames":["Drug: Dulaglutide","Drug: Placebo"]},{"label":"0.75 mg Dulaglutide","type":"EXPERIMENTAL","interventionNames":["Drug: Dulaglutide"]},{"label":"1.5 mg Dulaglutide","type":"EXPERIMENTAL","interventionNames":["Drug: Dulaglutide"]}],"interventions":[{"name":"Dulaglutide","otherNames":["LY2189265"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have type 2 diabetes, treated with diet and exercise, with or without metformin and/or basal insulin. Metformin and/or basal insulin dose must be stable for at least 8 weeks prior to study screening.\n* Have HbA1c \\>6.5% to ≤11% at screening visit. If newly diagnosed and not on medicine for diabetes, HbA1c must be between \\>6.5 % to ≤9%.\n* Have a BMI (body mass index) \\>85 percentile for age, gender and body weight ≥50 kilograms (110 pounds).\n\nExclusion Criteria:\n\n* Known type 1 diabetes, or positive GAD65 or IA2 antibodies, or history of diabetic ketoacidosis or hyperglycemic hyperosmolar syndrome.\n* A history of, or at risk for pancreatitis.\n* Self or family history of Multiple Endocrine Neoplasia (MEN) type 2A or B, thyroid C-cell hyperplasia or medullary thyroid cancer, or a blood calcitonin result ≥20 picograms per milliliter (pg/ml) at screening.\n* A systolic blood pressure of ≥160 millimeters of mercury (mmHg) or diastolic ≥100 mmHg.\n* Active or treated cancer.\n* A blood disorder where an accurate HbA1c may not be obtainable.\n* A female of childbearing age, sexually active and not on birth control.\n* Pregnant or plan to be pregnant during the study, or breastfeeding.\n* Taking any diabetic medication other than metformin or basal insulin and have not stopped it 3 months prior to the screening visit (6 weeks for bolus or mealtime insulin).\n* Have taken oral steroids within the last 60 days or more than 20 days use within the past year or 1000 micrograms fluticasone propionate per day.\n* Using prescription weight loss medications in the last 30 days, or plan to use.\n* Taking psychiatric medications for depression or illness or attention deficit hyperactivity disorder (ADHD) if, the doses has changed within the last 3 months.","healthyVolunteers":false,"sex":"ALL","minimumAge":"10 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses) at Week 26","description":"HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least square (LS) mean in HbA1c was calculated using a restricted maximum likelihood (REML) based mixed-effects model for repeated measures (MMRM) and adjusted by, baseline + insulin Use + metformin Use + treatment + time + treatment\\*time (Type III sum of squares). Variance-covariance structure = unstructured (for actual value) / unstructured (for change from baseline).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"0.24"},{"groupId":"OG001","value":"-0.7","spread":"0.16"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HbA1c (Individual Doses) at Week 26","description":"HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. LS mean in HbA1c was calculated using a REML based MMRM and adjusted by, baseline + insulin use + metformin use + treatment + time + treatment\\*time (Type III sum of squares). Variance-covariance structure = unstructured (for actual value) / unstructured (for change from baseline).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"0.24"},{"groupId":"OG001","value":"-0.5","spread":"0.22"},{"groupId":"OG002","value":"-1.0","spread":"0.22"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Blood Glucose (FBG) at Week 26","description":"Fasting blood glucose is a test to determine how much glucose (sugar) is in a blood sample after an overnight fast. Least squares (LS) means were calculated using a mixed-effects model for repeated measures (MMRM) analysis and adjusted by baseline, strata, treatment, time, treatment\\*time, (Type III sum of squares). Variance-Covariance structure = Unstructured (for actual value) / Unstructured (for change from baseline). Strata refer to: insulin use + metformin use + baseline HbA1c group \\[ less than (\\<) 8%, greater than or equal to (\\>=) 8%).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.96","spread":"0.45"},{"groupId":"OG001","value":"-0.47","spread":"0.41"},{"groupId":"OG002","value":"-1.54","spread":"0.41"},{"groupId":"OG003","value":"-1.03","spread":"0.29"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HbA1c ≤7.0%","description":"The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.42","spread":null},{"groupId":"OG001","value":"60.00","spread":null},{"groupId":"OG002","value":"53.19","spread":null},{"groupId":"OG003","value":"56.52","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Body Mass Index (BMI) at Week 26","description":"BMI is an estimate of body fat based on body weight divided by height squared. LS mean were calculated using a MMRM analysis and adjusted by baseline, strata, treatment, time, treatment\\*time, (Type III sum of squares). Variance-Covariance structure = Unstructured (for actual value) / Unstructured (for change from baseline). Strata refer to: insulin use + metformin use + baseline HbA1c group (\\< 8%, \\>= 8%).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"0.21"},{"groupId":"OG001","value":"-0.2","spread":"0.20"},{"groupId":"OG002","value":"-0.1","spread":"0.19"},{"groupId":"OG003","value":"-0.1","spread":"0.14"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Self-Reported Events of Hypoglycemia","description":"Summary and analysis of Incidence of all hypoglycemia with Plasma Glucose \\<54mg/dL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.96","spread":null},{"groupId":"OG001","value":"3.92","spread":null},{"groupId":"OG002","value":"3.85","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Requiring Rescue for Severe, Persistent Hyperglycemia","description":"Percentage of Participants Requiring Rescue for Severe, Persistent Hyperglycemia was summarized.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.6","spread":null},{"groupId":"OG001","value":"3.9","spread":null},{"groupId":"OG002","value":"1.9","spread":null},{"groupId":"OG003","value":"2.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adjudicated Pancreatitis","description":"The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively at 26 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Pancreatic Enzymes at Week 26","description":"Serum Amylase (total and pancreas-derived) and lipase concentrations were measured.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":"17.36"},{"groupId":"OG001","value":"4.80","spread":"9.39"},{"groupId":"OG002","value":"6.50","spread":"8.91"},{"groupId":"OG003","value":"5.64","spread":"9.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.60","spread":"9.94"},{"groupId":"OG001","value":"1.77","spread":"4.72"},{"groupId":"OG002","value":"2.90","spread":"6.10"},{"groupId":"OG003","value":"2.32","spread":"5.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.23","spread":"31.99"},{"groupId":"OG001","value":"4.37","spread":"8.28"},{"groupId":"OG002","value":"3.88","spread":"6.63"},{"groupId":"OG003","value":"4.12","spread":"7.47"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Thyroid Treatment-Emergent Adverse Events","description":"Number of Participants with Thyroid Treatment-Emergent Adverse Events were summarized.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Serum Calcitonin at Week 26","description":"Change from Baseline in Serum Calcitonin was evaluated.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.38","spread":"1.70"},{"groupId":"OG001","value":"0.28","spread":"0.72"},{"groupId":"OG002","value":"0.10","spread":"0.50"},{"groupId":"OG003","value":"0.19","spread":"0.62"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Allergic, Hypersensitivity Reactions","description":"The percentage of Participants with Allergic and hypersensitivity reactions that were considered possibly related to study drug by the investigator are presented. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"3.9","spread":null},{"groupId":"OG002","value":"1.9","spread":null},{"groupId":"OG003","value":"2.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Injection Site Reactions","description":"The percentage of participants with at least one treatment-emergent injection site reaction is presented. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.8","spread":null},{"groupId":"OG001","value":"9.8","spread":null},{"groupId":"OG002","value":"7.7","spread":null},{"groupId":"OG003","value":"8.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Anti-Dulaglutide Antibodies","description":"Dulaglutide anti-drug antibodies (ADA) were assessed at baseline, Weeks 26 and 56. A participant was considered to have treatment-emergent (TE) dulaglutide ADAs if the participant had at least 1 titer that was TE relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics (PK): Maximum Concentration of Dulaglutide at Steady-state (Cmax,ss)","description":"PK: Maximum Concentration of Dulaglutide at steady-state (Cmax,ss) was derived by a population pharmacokinetics approach. As part of addendum, additional PK samples were taken at week 9.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"62","spread":null}]}]}]},{"type":"SECONDARY","title":"PK: Area Under the Concentration Time Curve Over a 1-week Interval of Dulaglutide at Steady-State [AUC(0-168)ss]","description":"PK: Area Under the Concentration Time Curve over a 1-week interval of Dulaglutide at Steady-State \\[AUC(0-168)ss\\] was derived by a population pharmacokinetics approach. As part of addendum, additional PK samples were taken at week 9.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4170","spread":null},{"groupId":"OG001","value":"8350","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":51},"commonTop":["Diarrhoea","Headache","Vomiting","Nausea","Abdominal pain upper"]}}}